Ultra-Long-Acting Platform
搜索文档
Ascletis Announces First Participants with Obesity or Overweight Dosed in Its U.S. 12-week Phase IIa Study Evaluating Once-Monthly Subcutaneous Depot Formulation of Small Molecule GLP-1R Agonist ASC30
Prnewswire· 2025-07-28 08:15
- First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 12-week Phase IIa study with once-monthly subcutaneous (SQ) depot formulation of small molecule GLP-1 receptor agonist ASC30. - Ultra-long-acting SQ depot formulation of small molecule ASC30 demonstrated a 36-day half-life in participants with obesity in the Phase Ib study, supporting once monthly administration. - Phase Ib study also demonstrated that compared to ...
Ascletis Announces First Participants Dosed in U.S. Phase I Clinical Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor for the Treatment of Psoriasis
Prnewswire· 2025-06-18 08:00
药物研发进展 - ASC50是一种针对白细胞介素-17(IL-17)的口服小分子抑制剂，用于治疗银屑病等自身免疫和炎症性疾病 [2] - ASC50已完成I期临床试验首例健康受试者给药，该试验在美国多中心开展，采用随机、双盲、安慰剂对照设计 [2][3] - 临床前数据显示ASC50具有更高的口服暴露量、更长半衰期和强效作用，有望成为同类最佳每日一次口服疗法 [1] 公司技术平台 - 公司拥有自主开发的人工智能辅助结构药物发现平台(AISBDD)和超长效技术平台(ULAP) [4] - 利用上述平台开发了多个内部候选药物，包括主打产品ASC30(一种GLP-1R激动剂) [4] 公司背景 - 公司是一家专注于代谢疾病领域创新疗法开发的综合性生物技术企业 [4] - 公司在香港交易所上市(股票代码:1672) [4] - 创始人兼CEO表示期待在近期获得ASC50的顶线数据 [4]
